0.70
+0.003(+0.43%)
Currency In USD
| Previous Close | 0.7 |
| Open | 0.7 |
| Day High | 0.71 |
| Day Low | 0.69 |
| 52-Week High | 2.29 |
| 52-Week Low | 0.66 |
| Volume | 118,067 |
| Average Volume | 144,142 |
| Market Cap | 27.43M |
| PE | -1.26 |
| EPS | -0.56 |
| Moving Average 50 Days | 0.83 |
| Moving Average 200 Days | 1.09 |
| Change | 0 |
If you invested $1000 in SCYNEXIS, Inc. (SCYX) 10 years ago, it would be worth $8.1 as of July 12, 2025 at a share price of $0.703. Whereas If you bought $1000 worth of SCYNEXIS, Inc. (SCYX) shares 5 years ago, it would be worth $102.93 as of July 12, 2025 at a share price of $0.703.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
GlobeNewswire Inc.
May 28, 2025 12:30 PM GMT
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GS
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
GlobeNewswire Inc.
Dec 18, 2024 1:00 PM GMT
JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has comple